Suppr超能文献

肝移植后原发性硬化性胆管炎复发的危险因素。

Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation.

作者信息

Cholongitas Evangelos, Shusang Vibhakorn, Papatheodoridis George V, Marelli Laura, Manousou Pinelopi, Rolando Nancy, Patch David, Rolles Keith, Davidson Brian, Burroughs Andrew K

机构信息

Liver Transplantation and Hepatobiliary Unit, Royal Free Hospital, London, UK.

出版信息

Liver Transpl. 2008 Feb;14(2):138-43. doi: 10.1002/lt.21260.

Abstract

Liver transplantation (LT) is the only therapeutic option for end-stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation for PSC (42 male, mean age 41.9 yr). Clinical and laboratory data, activity/extension and treatment of ulcerative colitis (UC), post-LT cytomegalovirus (CMV) infection, and immunosuppression were evaluated. Determination of rPSC was made by radiological and histological findings. Exclusion criteria were ABO blood group incompatibility, hepatic artery stenosis, and biliary strictures occurring in <3 months post-LT. A total of 48 (70%) patients had PSC and UC pre-LT. rPSC occurred in 7 of 53 (13.5%, 2 patients with de novo UC) who were alive 1 yr after LT and/or met inclusion/exclusion criteria: median 60 (4-120) months. No patient without post-LT UC had rPSC: 0 of 20 vs. 7 of 26 with post-LT UC (P = 0.027). The multivariate logistic regression analysis showed that maintenance steroids for UC (>3 months) post-LT was the only risk factor significantly associated with rPSC (P = 0.025). In conclusion, the presence of UC post-LT, and the need for maintenance steroids post-LT, which is an independent factor, are associated with rPSC. These findings could help elucidate a possible mechanism of PSC pathogenesis.

摘要

肝移植(LT)是终末期原发性硬化性胆管炎(PSC)的唯一治疗选择,但部分患者肝移植后PSC会复发(rPSC)。我们研究的目的是评估与rPSC相关的危险因素。1989年至2004年间,69例因PSC接受移植的患者(42例男性,平均年龄41.9岁)。对临床和实验室数据、溃疡性结肠炎(UC)的活动/范围及治疗、肝移植后巨细胞病毒(CMV)感染和免疫抑制情况进行了评估。通过影像学和组织学检查结果确定rPSC。排除标准为ABO血型不合、肝动脉狭窄以及肝移植后3个月内出现的胆管狭窄。共有48例(70%)患者肝移植前患有PSC和UC。53例肝移植后存活1年及/或符合纳入/排除标准的患者中有7例发生rPSC(13.5%,2例为新发UC):中位时间为60(4 - 120)个月。肝移植后无UC的患者无rPSC发生:20例中0例,而肝移植后有UC的26例中有7例(P = 0.027)。多因素逻辑回归分析显示,肝移植后用于UC的维持性类固醇治疗(>3个月)是与rPSC显著相关的唯一危险因素(P = 0.025)。总之,肝移植后存在UC以及肝移植后需要维持性类固醇治疗(这是一个独立因素)与rPSC相关。这些发现有助于阐明PSC发病机制的一种可能机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验